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Effectiveness of community participation in tuberculosis 
control 
T N Achoki,  C Shilumani, A Beke  
To the Editor: Tuberculosis (TB) has re-emerged as an 
important global public health issue, particularly with the 
advent of HIV and AIDS.1-3 Sub-Saharan Africa has the highest 
incidence of TB in the world, estimated at over 350 cases 
per 100 000.1 With many of its provinces being rural and 
characterised by limited access to health services, South Africa 
ranked fifth globally among high TB burden countries in 2007.4  
In low-resource settings where health systems barely cope with 
increased disease burdens, community participation has come 
to the fore as a pivotal measure for successful programming. 
We sought to evaluate the performance of a community-
based TB project piloted in a rural sub-district in the Eastern 
Cape province of South Africa. The project, implemented by 
an international non-governmental organisation (NGO) over 
2 years, had the key objective of achieving the global target of 
an 85% treatment success rate1 among TB patients registered 
in the sub-district. It mainly comprised advocacy measures 
to increase community awareness on aspects of TB control 
which, it was envisaged, would enhance treatment-seeking 
behaviours at individual, household and community levels. 
It was implemented in close collaboration with community 
entities such as rural clinics, local schools and civil society 
organisations (CSOs). The CSOs received support to initiate 
community microprojects such as community gardens to 
enhance nutrition among affected communities, TB contact 
and defaulter tracing to improve adherence to treatment, 
and smoking cessation campaigns. However, in undertaking 
these activities there was little focus on the other technical 
components of an effective TB programme, such as quality 
microscopy, timely recording and reporting.  
A total of 463 new TB patients were registered in the pilot 
sub-district over the 2-year period, 145 in 2004 and 318 in 
2005, representing a >100% increase in new caseload without 
any reported exogenous contributory factor other than 
the introduction of the community project. A comparable 
neighbouring sub-district (N=631) registered an increase of 
only 3.0% during this time.
The average age of the patients was 38.0 years (95% 
confidence interval (CI) 36.52 - 39.45). Males were older, 
with a mean age of 40.5 years (95% CI 38.56 - 42.3 years) 
compared with 34.9 years (95% CI 32.7 - 37.2) for females. For 
both genders the age category with the highest proportion of 
patients was between 15 and 54 years; females peaked at 15 - 
44 years and males at 25 - 54.
We used data from the pilot sub-district’s electronic TB 
register to analyse the quarterly performance of successive 
treatment cohorts and made comparisons over the period 
between quarter 1, 2004 and quarter 4, 2005. Bacteriological 
coverage declined from 80% to 50%, new smear conversion 
rates dropped from 60% to 30%, and treatment success 
rate dropped from 60% to 38%.  TB patients reported as 
‘not evaluated’ increased to 45% in quarter 4, 2005, from 
insignificant proportions reported in the preceding quarters. 
Analysing determinants of treatment success revealed that 
patients registered in 2005 were 75.4% less likely to achieve 
treatment success than those in 2004. Similarly, patients who 
transferred into the treatment centres located in the pilot 
sub-district during the same period were less likely to be 
successfully treated (Table I). 
We are cognisant of limitations in this evaluation. Reliable 
causal inference to a specific intervention as responsible for the 
changes observed was difficult for a descriptive study of this 
nature. Reliance on secondary data, the quality of which cannot 
be readily ascertained, is also a weakness. However, attempts 
were made to mitigate for quality issues through rigorous data 
cleaning and collation before analysis. 
We conclude that community participation alone is 
inadequate to improve the performance of a TB control 
programme. Planning a holistic and comprehensive approach 
should seek to strengthen the programme’s technical and 
organisational capacity5 before engaging in purely community 
interventions. Failure to observe this logical relationship would 
result in suboptimal performance. Efforts to increase demand 
for health services should be cognisant of the health system 
capacity. 
We recommend further research and sharing of best practices 
and evidence-based approaches of harnessing community-based 
interventions to improve health outcomes. 
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Table I. Determinants of treatment success (463 patients)
Treatment success             Odds ratio (95% CI)      p-value
Sex (male)             0.822 (0.55 - 1.22)      0.333
Transferred in patients        0.526 (0.35 - 0.79)*      0.002
Age category             1.11 (0.99 - 1.26)      0.083
Year of registration 2005      0.246 (0.16 - 0.38)      0.001
*Statistically significant odds ratios are set in bold. 
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CFTR structural rearrangements are not a major mutational 
mechanism in black and coloured southern African patients 
with cystic fibrosis
Candice Lee De Carvalho, Michele Ramsay
To the Editor:  Exon copy number variants (CNVs) in the 
CFTR gene have been identified as a new type of mutation in 
cystic fibrosis (CF) patients.1  Most of these mutations have 
been identified in CF patients of European origin; however, a 
deletion of the promoter and exons 1 and 2 of the CFTR gene 
was detected in two African American families.2
To increase the CFTR mutation detection rate in black and 
coloured South African CF patients for molecular diagnosis, we 
tested patients with a clinical phenotype of CF, and at least one 
unidentified CFTR mutation, for exon CNVs in the CFTR gene: 
24 coloured patients (of Khoisan, Malay, European and African 
admixture), most of whom originate from the Western Cape, 
and 18 black patients (sub-Saharan African origin) were tested.  
Multiplex ligation-dependent probe amplification (MLPA) 
that detects deletions and duplications based on the principles 
of complementary probe binding, ligation and amplification 
with a comparison of patient data to control data, was used 
(CFTR P091 kit).3  Controls were matched for ethnicity and 
geographical region of origin.  
A heterozygous deletion of exon 2 was detected in a single 
black CF patient, using both MLPA and semi-quantitative 
fluorescent PCR. The deletion breakpoints were determined 
as c.54-1161_c.164+1603del2875 and a mutation mechanism 
was suggested based on a small direct repeat at the 5’ and 
3’ breakpoints.4 This mutation causes the deletion of amino 
acids 91 to 163, corresponding to the deletion of the first two 
transmembrane regions, two cytoplasmic topological domains 
and one extracellular topological domain of the chloride 
channel (http://www.expasy.org, http://www.genet.sickkids.
on.ca/cftr/). The anticipated consequence would be complete 
loss of function. This patient had one positive sweat test and 
other symptoms suggestive of CF, including respiratory failure. 
He has since been lost to follow-up.
This mutation was not detected in any of the other patients, 
and may be unique to this family. No other CNVs were 
detected.  It would therefore not be cost effective to include 
it in the diagnostic panel of mutations in black and coloured 
patients with symptoms suggestive of CF.  Although the 
sample size was small, this report suggests that exon copy 
number variants of CFTR is not a major mutational mechanism 
giving rise to CF in black and coloured southern African CF 
patients.  
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Ethnic classification. The rationale for ethnic classification is 
that the study was done specifically to identify mutations in ethnic 
groups in which CFTR mutation detection in South Africa is low.
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